Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,773 signal articles · 72 in last 24h · 148,348 total before filter · latest 1h ago
72last 24h
975last 7d
109● bullish (7d)
124● bearish (7d)
212publishers
AllMacro369Earnings115M&A98Regulatory8Product11Analyst11
✕ clear all filtersticker: CVSSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Health Care Stocks Built For Higher Rates
Simply Wall St.2d agoneutral
3 Health Care Stocks Built For Higher Rates

When the Federal Reserve lifts rates and signals they may stay elevated for years, the easy-growth playbook breaks. Cash flows today matter more than promises tomorrow, and investors start to care a lot about balance sheet strength, pricing power and dependable dividends. This article walks through three large cap quality defensive stocks that screen well under those rules and explains how the latest Fed move could affect each one. The three stocks below are a sample of what this quality...

How Tech Leaders Are Navigating AI’s ROI Problem
WSJ2d agoneutralVIDEO
How Tech Leaders Are Navigating AI’s ROI Problem

At the WSJ Leadership Institute's Technology Council Summit, technology executives from McKinsey, FedEx and CVS Health discuss how they are navigating the rising costs of generative AI and finding real business value.

CVS’s Turnaround Faces Its Next Test
Barrons.com45d agoneutral
CVS’s Turnaround Faces Its Next Test

CVS Health reports earnings Wednesday, with analysts expecting another solid quarter and looking for potential guidance upside from its Aetna insurance and Caremark pharmacy-benefit businesses.

CVS Health (CVS) Faces Henry Ford Health Lawsuit Over $29 Million 340B Claims
Simply Wall St.57d agobearish
CVS Health (CVS) Faces Henry Ford Health Lawsuit Over $29 Million 340B Claims

Henry Ford Health has filed a lawsuit against CVS Health (NYSE:CVS) alleging fraudulent reimbursement practices tied to the federal 340B drug discount program. The complaint claims CVS manipulated pricing and engaged in retaliatory behavior, which Henry Ford Health says led to losses of more than US$29 million. The case adds to a series of disputes between large health systems and pharmacy operators over how 340B program discounts are administered. For investors following CVS Health, this...

FTC Reaches Settlement With CVS Health Over Insulin Prices
Barrons.com66d agoneutral
FTC Reaches Settlement With CVS Health Over Insulin Prices

The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.

CVS Health (CVS) Under the Microscope After Recent Healthcare Report
Insider Monkey88d agoneutral
CVS Health (CVS) Under the Microscope After Recent Healthcare Report

CVS Health Corporation (NYSE:CVS) is one of the 10 Cheap Jim Cramer Stocks to Invest In Right Now. The New York Times, in an article published on June 11, 2026, pointed to two federal reports from the Department of Health and Human Services and stated that CVS Health Corporation (NYSE:CVS) and other major Medicare Advantage […]

CVS Health Balances 340B Lawsuits With GLP 1 Growth Prospects
Simply Wall St.105d agobearish
CVS Health Balances 340B Lawsuits With GLP 1 Growth Prospects

CVS Health (NYSE:CVS) is facing lawsuits from multiple health systems that allege the company diverted hundreds of millions of dollars in savings tied to the federal 340B drug discount program. At the same time, CVS Health is expanding access to GLP-1 weight management drugs through new formulary decisions, including the reintroduction of Zepbound and removal of barriers for Foundayo. These developments come as pharmacy benefit manager practices receive increased attention from regulators...

CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment
Simply Wall St.121d agobearish
CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment

CVS Health (NYSE:CVS) has been hit with two lawsuits from major hospital systems tied to the federal 340B drug discount program. The University of Kansas Hospital Authority and the University of Michigan Hospitals and Health Centers allege CVS Health improperly profited from 340B discounts. Combined claimed damages exceed $60 million, raising legal, financial, and reputational questions for the company. CVS Health comes into this legal pressure with its shares at $93.28 and a return of...